Patients should also be educated and encouraged to report new or worsening symptoms
Additionally, GLP-1 receptor agonists (RAs) have direct impacts on synaptic (Wang et al., 2013) and microglial (Spielman et al., 2017) activities as well as neuroprotective qualities by reestablishing brain energy metabolism (Daniele et al., 2015
At Victory Mens Health, we specialize in personalized treatment plans designed to match your lifestyle, needs, and goals
Key expectations for long-term treatment include: Weight loss velocity decreases over time, with most reduction occurring in the first 912 months Plateaus lasting 48 weeks are common and do not indicate treatment failure Individual response varies based on genetics, baseline metabolic health, adherence, and lifestyle factors Continued medication use is typically necessary to maintain weight loss Non-scale victoriesimproved mobility, reduced medication burden for comorbidities, better quality of lifeare equally important outcomes Patients should also be aware of potential adverse effects that may affect long-term adherence
Tirzepatide occupies a unique place in modern peptide pharmacology: it is the first commercially synthesized dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
Rybelsus belongs to the drug class called glucagon-like peptide-1 (GLP-1) receptor agonists
